1. The Inhibition of Wnt Restrain KRASG12V-Driven Metastasis in Non-Small-Cell Lung Cancer
   Pei-Shan Hung et al, 2020, Cancers CrossRef
2. The Prevalence and Concurrent Pathogenic Mutations of KRASG12C in Northeast Chinese Non-small-cell Lung Cancer Patients
   Yan Liu et al, 2021, CMAR CrossRef
3. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China
   Yongchun Zhou et al, 2021, Front. Oncol. CrossRef
4. Characterization With KRAS Mutant Is a Critical Determinant in Immunotherapy and Other Multiple Therapies for Non-Small Cell Lung Cancer
   Mo Shen et al, 2022, Front. Oncol. CrossRef
5. Impact of KRAS Mutation Subtypes and Co-Occurring Mutations on Response and Outcome in Advanced NSCLC Patients following First-Line Treatment
   Yingjia Sun et al, 2022, JCM CrossRef
6. The Role of Neighborhood Air Pollution Exposure on Somatic Non-Small Cell Lung Cancer Mutations in the Los Angeles Basin (2013–2018)
   Noémie Letellier et al, 2022, IJERPH CrossRef
7. Light at the end of the tunnel: Clinical features and therapeutic prospects of KRAS mutant subtypes in non-small-cell lung cancer
   Liyuan Gao et al, 2022, Front. Genet. CrossRef
8. The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
   Firas Batrash et al, 2023, Exp Hematol Oncol CrossRef